P
POINT Biomedical
Pharmaceutical company developing technologies for imaging and drug deliveries
About POINT Biomedical
A privately held pharmaceutical company that develops technologies for imaging and drug delivery. Its main technology is based on an ultrasonically responsive, two-layer, biodegradable microsphere that can be used for both diagnostic imaging and therapeutic drug delivery.
One of its key products is CARDIOsphere, a pharmaceutical agent used for assessing myocardial perfusion, which is blood flow to the heart muscle. This product is used in conjunction with ultrasound imaging to provide better diagnostic information for patients with suspected coronary artery disease.
The company's business model focuses on the development and commercialization of its proprietary technology platform. It serves the healthcare market, specifically in the areas of cardiology and medical imaging. The company generates revenue through the sale of its products to hospitals and clinics.
Source: Dealroom company dataAt a glance
- Founded
- 1996
- Headquarters
- San Carlos, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
- DVDeNovo Ventures
CHL Medical Partners- VCVedanta Capital
Invesco
SR One
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about POINT Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See POINT Biomedical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.